World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG

Cision PR Newswire by Cision PR Newswire
June 24, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);
company also appoints Chief Commercial Officer

DEL MAR, Calif., June 24, 2026 /PRNewswire/ — CeleCor Therapeutics has submitted the final section of its New Drug Application for the company’s investigational heart-attack drug, zalunfiban (DisaggproTM), to the U.S. Food and Drug Administration.


CeleCor logo

The NDA filing follows presentation in November of positive Phase 3 results from its CeleBrate study at the American Heart Association Scientific Sessions, as well as publication of the results in The New England Journal of Medicine Evidence.

The company also appointed Michael Moye as Chief Commercial Officer to lead commercial strategy and operations to support zalunfiban. Moye joins CeleCor after holding key leadership positions at companies including Idorsia, Shire and Johnson & Johnson.

Zalunfiban has FDA Fast Track status and was granted Rolling Review in January. This allows submission of documents and data as they become available, enabling regulators to begin their review early and creating the potential to shorten the review timeline.

The multinational CeleBrate study found that rapid zalunfiban treatment for STEMI heart attacks at first point of medical contact lowered risk of more severe heart damage in combination with other serious heart-attack complications. STEMI (ST-segment elevation) heart attacks are the most severe form of heart attack; the priority in treating them is opening the coronary artery as soon as possible to prevent death or irreversible heart damage.

About zalunfiban
Zalunfiban is an investigational agent; it has not been approved for any use and its safety and efficacy have not been established. Zalunfiban is a novel small-molecule inhibitor of the platelet GPIIb/IIIa receptor and was specifically designed for subcutaneous injection at the first point of medical contact for STEMI heart attacks.

About CeleCor Therapeutics
CeleCor Therapeutics was founded to improve the treatment of STEMI heart attacks at the first point of medical contact. For more updates, follow us on LinkedIn.

CONTACT: Rob Hillman, rhillman@celecor.com 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-302809063.html

SOURCE CeleCor Therapeutics, Inc.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Thunes Expands Real-Time Payouts to Bhutan, Unlocking the Nation’s Remittance Market

    0 shares
    Share 0 Tweet 0
  • Bloomberg Indices and HKEX Launch Co-branded Offshore RMB Bond Index Family to Support Growing Investor Demand in the Dim Sum Bond Market

    0 shares
    Share 0 Tweet 0
  • CANACCORD GENUITY GROUP INC. ANNOUNCES SALE OF ITS WEALTH MANAGEMENT BUSINESS IN THE UK & CROWN DEPENDENCIES TO CENTERBRIDGE PARTNERS, L.P. AND MUBADALA INVESTMENT COMPANY PJSC

    0 shares
    Share 0 Tweet 0
  • SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Portillo’s Inc. (NASDAQ: PTLO) — Investors Who Suffered Losses Are Encouraged to Contact the Firm.

    0 shares
    Share 0 Tweet 0
  • EFICYENT to Join Banks and Fintech Companies at Singapore FinTech Festival 2026

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler